Combination therapy: For patients with type 2 diabetes mellitus to improve glycemic control in combination with sulfonylurea derivatives (triple combination: metformin + sitagliptin + sulfonylurea derivative), when diet and exercise regimen are combined with two of these three drugs (metformin, sitagliptin or derivatives sulfonylureas) do not lead to adequate glycemic control
Patients self-inject Saxenda daily, or Wegovy, Ozempic, Zepbound and Mounjaro weekly using a pre-filled auto-injector pen
In addition to cardiovascular benefits, dual GLP-1/amylin therapy is now being studied in various obesity-related conditions like nonalcoholic steatohepatitis, obstructive sleep apnea, chronic kidney disease, and heart failure with preserved ejection fraction, suggesting that these drugs could be used as a cornerstone therapy for the management of comprehensive metabolic syndrome rather than for just one indication
Wang L, Xu R, Kaelber DC, Berger NA